579 related articles for article (PubMed ID: 32412186)
1. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
2. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
3. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas.
Chen J; Li Y; Han X; Pan Y; Qian X
Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
5. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 5-Signature Predicting Survival of Patients with Lower-Grade Glioma.
Xiao H; Bai J; Yan M; Ji K; Tian W; Liu D; Ning T; Liu X; Zou J
World Neurosurg; 2019 Jun; 126():e765-e772. PubMed ID: 30853516
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
[TBL] [Abstract][Full Text] [Related]
8. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
9. A prognostic signature of five pseudogenes for predicting lower-grade gliomas.
Liu B; Liu J; Liu K; Huang H; Li Y; Hu X; Wang K; Cao H; Cheng Q
Biomed Pharmacother; 2019 Sep; 117():109116. PubMed ID: 31247469
[TBL] [Abstract][Full Text] [Related]
10. Identification and Potential Mechanisms of a 7-MicroRNA Signature That Predicts Prognosis in Patients with Lower-Grade Glioma.
Liu Z; Meng H; Fang M; Guo W
J Healthc Eng; 2021; 2021():3251891. PubMed ID: 34845420
[TBL] [Abstract][Full Text] [Related]
11. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
12. Development of a Prognostic Five-Gene Signature for Diffuse Lower-Grade Glioma Patients.
Zhang Q; Liu W; Luo SB; Xie FC; Liu XJ; Xu RA; Chen L; Su Z
Front Neurol; 2021; 12():633390. PubMed ID: 34295296
[No Abstract] [Full Text] [Related]
13. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.
Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
J Neurooncol; 2018 Mar; 137(1):127-137. PubMed ID: 29204839
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of an Autophagy-Related Five-Gene Signature for Lower-Grade Glioma Patients.
Guo JC; Wei QS; Dong L; Fang SS; Li F; Zhao Y
Front Oncol; 2021; 11():644443. PubMed ID: 33768004
[No Abstract] [Full Text] [Related]
15. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
[TBL] [Abstract][Full Text] [Related]
16. A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.
Wu Y; Peng Z; Gu S; Wang H; Xiang W
Comput Math Methods Med; 2022; 2022():2558548. PubMed ID: 35186111
[TBL] [Abstract][Full Text] [Related]
17. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W
J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210
[TBL] [Abstract][Full Text] [Related]
19. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.
Cheng W; Ren X; Zhang C; Han S; Wu A
J Neurooncol; 2017 Apr; 132(2):207-218. PubMed ID: 28091987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]